Hot Features
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase ... Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 20.5 | 17.7182368194 | 115.7 | 136.295 | 110.96 | 275899 | 119.70890389 | CS |
| 4 | 18.99 | 16.2016892757 | 117.21 | 136.295 | 100 | 280535 | 111.93363081 | CS |
| 12 | 16.01 | 13.3205757551 | 120.19 | 138.64 | 100 | 238828 | 118.41486807 | CS |
| 26 | 30.7 | 29.0995260664 | 105.5 | 151.18 | 72.225 | 270864 | 111.97206235 | CS |
| 52 | 113.89 | 510.488570148 | 22.31 | 151.18 | 20.35 | 232901 | 92.61465242 | CS |
| 156 | 123.8 | 998.387096774 | 12.4 | 151.18 | 11.1 | 176429 | 83.46399724 | CS |
| 260 | 123.8 | 998.387096774 | 12.4 | 151.18 | 11.1 | 176429 | 83.46399724 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.